Newbury Pharmaceuticals Q1: Initial Take - Redeye

Redeye leaves an initial comment following the Q1 report published by Newbury this morning. While net sales and EBIT came in below our estimates, we expected somewhat modest figures for the period. In line with more product launches coming up, we expect sales growth to follow. Overall, the Q1 report will likely only cause minor adjustments to our longer-term forecasts.

Länk till analysen i sin helhet: https://www.redeye.se/research/870664/newbury-pharmaceuticals-q1-initial-take?utm_source=finwire&utm_medium=RSS